Responses

other Versions

PDF
Extended report
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Response to Dr Bolland's eLetter

    Dear Editor,

    The work carried out by the authors on calcium and the cardiovascular risk is of primary importance. We thank the authors for questions and comments on the SEKOIA study, safety being a primary concern for us.
    The number of emergent adverse events reported in SEKOIA study was similar in the 3 treatments groups: 85.8%, 87.9% and 86.5% in the SrRan 1g, SrRan 2g and placebo groups as well as the number...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomized, placebo-controlled trial

    Dear Editor,

    We would like to reply to the recent letter by Murphy et al(1) regarding the possible influence of obesity and weight changes on the results of the SEKOIA trial of the efficacy and safety of strontium ranelate in knee osteoarthritis.2 Obesity and overweight are recognized risk factors for osteoarthritis,3 and so it is essential to include such patients in studies of potential treatments, since they are...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Strontium and cardiovascular events
    • Mark J Bolland, Senior Research Fellow
    • Other Contributors:
      • Andrew Grey

    Dear Editor,

    In the report of their trial of strontium ranelate in knee osteoarthritis, Reginster and colleagues state that "Strontium ranelate was well tolerated" and that "The safety profile of strontium ranelate was satisfactory, in line with knowledge of this agent" (1). However, contemporaneously, the European Medicines Agency recommended that the use of strontium ranelate be restricted because it increased the r...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
    • Claire-Louise Murphy, Rheumatology SpR
    • Other Contributors:
      • Eithne Murphy, Trevor Duffy, Miriam O'Sullivan, Maurice Barry

    Dear Editor,

    We read with interest the paper regarding Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo- controlled trial. We note the exclusion criteria included secondary knee osteoarthritis. On review of the results section it appears that many of the patients both the randomised and the intention to treat groups e.g. the stronti...

    Show More
    Conflict of Interest:
    None declared.